Immunosenescence, the age-related decline in our body's ability to fight off infections and mount an immune response, is something we should all want to avoid.

Mitochondria are central to healthy immune system aging; specifically, the ability to recycle old, dysfunctional mitochondria and replace them with new ones, termed "mitophagy" (mitochondrial autophagy). Unfortunately, mitochondrial "quality control" also declines with age. 

Enter urolithin A, a gut-derived postbiotic that activates mitophagy and is often followed by mitochondrial biogenesis. It's designed to clear dysfunctional mitochondria and rebuild healthier ones—precisely the processes that drift with age.

In a new month-long study, urolithin A supplementation promoted a more "youthful" immune system environment characterized by a robust immune response and a lower inflammatory burden, alongside improved mitochondrial efficiency.

In today's newsletter, we'll unpack what these shifts mean for immunosenescence and metabolic health, how they align with urolithin A's mechanism of action, and where the limitations lie. We'll also explore what trials show for muscle strength and endurance, so you can decide whether this "mitochondrial" supplement belongs in your toolbox.

Urolithin A promotes "younger" immune cells

Researchers tested whether four weeks of daily urolithin A (1,000 mg of Mitopure) could shift markers of immune aging in a group of 50 healthy adults aged 45–70. Participants took urolithin A (or a placebo) for 28 days, then had deep immune phenotyping tests to see whether their immune cells behaved more “youthfully.”

Over four weeks, the intake of urolithin A led to high plasma concentrations of both the parent compound (urolithin A) and its conjugated form, urolithin A glucuronide. This confirmed its oral bioavailability. Adverse events were rare and similar to placebo—no significant changes were observed in kidney function parameters or liver enzymes after 28 days in either group.

The headline result was a remodeling of CD8+ T cells. 

As we age, a critical subpopulation of immune cells called naive-like CD8+ cells declines—contributing to the loss of responsiveness to novel pathogens and a vulnerability to infectious diseases.

After 4 weeks, the participants taking urolithin A had more naive-like CD8+ cells and fewer exhausted CD8+ cells—less old and more fresh ones ready to respond. Urolithin A also increased a marker of cell proliferation known as Ki-67, and reduced TOX (a transcription factor linked to T-cell exhaustion). These changes are opposite to those typically occurring in aging.

Energy handling inside immune cells shifted too. CD8+ T cells—especially the naive subset—became less dependent on glucose and more capable of oxidizing fats and amino acids. Instead of relying on quick sugar, urolithin A pushed cells toward steadier, mitochondria-driven fuel, a sign of better metabolic fitness and resilience. Natural killer cells showed a similar pattern of reduced glucose dependence and enhanced fat/amino acid metabolism, while CD4+ T cells and B cells changed little.

Innate immunity is also affected

Urolithin A increased a mature, cytotoxic subset of natural killer cells and shifted monocytes (the largest type of white blood cells) toward a less inflammatory state. Functionally, these monocytes "ate up" more E. coli when challenged, hinting at better first-line surveillance.

What about the mitochondria themselves? Although overall mitochondrial mass didn’t change, CD8+ T cells did upregulate PGC-1α (the master switch for mitochondrial biogenesis). Results also showed hallmarks of mitophagy (clearing damaged mitochondria) followed by enhanced signs of renewal. The mitochondria that were being cleared were simultaneously being replaced. That's good news.

Across several arms of the immune system the signal was that of a heightened immune response (when needed) without raising levels of baseline or chronic inflammation. When activated in the lab, CD8+ T cells from the urolithin A group released more of a key defense signal (TNF), showing a stronger on-demand response. At rest, one signaling molecule (IL-2) was slightly lower, and there was no broad increase in inflammatory cytokines. The immune system wasn’t more inflamed at baseline after urolithin A supplementation, but it was more primed to respond.

Gene-level readouts pointed in the same direction. In CD8+ T cells, activity shifted toward programs linked to fresher, more ready-to-respond cells and away from programs tied to fatigue or dysfunction.

By improving mitochondrial quality control and rerouting cellular fuel toward oxidation, urolithin A pushes aging-prone immune cells toward a more youthful phenotype and function—more naive, less exhausted, and better at responding when needed, without promoting systemic inflammation. If replicated in larger, longer trials with clinical outcomes, this supplement could emerge as a mitochondrial-centric strategy to counter certain aspects of immunosenescence and bolster vaccine or infection responses in midlife and beyond.

Performance in a pill?

Urolithin A is a postbiotic—a compound our gut microbes can make after we eat foods rich in ellagitannins, such as pomegranates, strawberries, and walnuts. 

Ellagitannins and ellagic acid in these foods can be converted by select gut bacteria into urolithin A, but not everyone has the right microbes—people fall into one of three defined “metabotypes”: A (urolithin A producers), B (who make some urolithin A plus other urolithins), or 0 (urolithin non-producers). Only a minority convert these foods efficiently—about 40% are strong urolithin A producers. Direct urolithin A supplements (e.g., purified urolithin A such as that used in the study discussed today) bypass this variability.[1]

Urolithin A is best known as a mitophagy inducer. In animals, it extends lifespan and improves muscle function, and in humans it’s been tested for muscle, immune, and recovery outcomes. 

The most reliable wins are for strength and endurance at the muscle level.

• A month-long study in older adults (average age of 71), 1,000 mg/day of urolithin A improved muscle endurance and biomarkers of mitochondrial health.[3]

• In a trial of middle-aged, low-fitness adults, urolithin A supplementation led to a 10–12% increase in lower-body muscle strength, a 10–15% increase in VO₂ peak, and better performance on a 6-minute walk test, even when participants didn't engage in structured exercise training over the 4-month study.[4]

Athlete data are more mixed.

• In highly trained distance runners completing a month-long altitude camp, urolithin A did not improve their time trial performance but was associated with lower perceived exertion and reduced creatine kinase (a marker of muscle damage) after hard efforts. And while VO₂max rose more within the urolithin A group, the change wasn't different compared to a placebo. This suggests recovery benefits rather than a direct performance boost in more trained populations.[5]

• For resistance training, a small 8-week trial in trained men reported improvements in strength and muscular endurance with 1,000 mg/day of urolithin A alongside reductions in inflammation and oxidative stress markers, but the sample was tiny and needs confirmation.[6]

So, it's not "exercise in a pill," but urolithin A certainly has a signal that (ideally when combined with exercise training) it may be a strategy to counteract age-associated declines in muscle quality or enhance adaptations to strength or endurance training in fit people. It all comes back to better mitochondrial quality control and lower systemic inflammation—mechanisms that give us confidence these strength and endurance gains probably aren't a fluke.

Toney AM, et al. Immunomodulatory Role of Urolithin A on Metabolic Diseases. Biomedicines. 2021; 9(2):192. https://doi.org/10.3390/biomedicines9020192

Final thoughts

Urolithin A is one of the rare “mitochondrial” supplements with multiple human randomized controlled studies. It’s not a magic performance pill, and effects likely depend on baseline fitness, training load, and duration of supplementation. If you are curious, the research-grade dosing in trials is 500–1,000 mg/day of purified urolithin A. Foods help, but microbiome differences mean many people won’t make much urolithin A from diet alone.

If replicated in larger, longer trials with clinical outcomes, urolithin A could emerge as a mitochondrial-centric strategy to counter aspects of immune aging and bolster vaccine or infection responses in midlife and beyond.

I was compelled enough by the data that I started supplementing with it. We'll see where it takes me.

Warm regards

— Rhonda and the FoundMyFitness team